The approval of this second site enhances production capacity, confirming continued patient access to CONTRAVE while reinforcing the company's broader commitment to obesity research and treatment.

Data to be shared during an ObesityWeek press conference include four of seven presentations supporting CONTRAVE and its utility in helping people lose weight BRENTWOOD, Tenn., Nov. 4, 2025 ...

Every weight loss journey is unique. It’s often a matter of finding what works best for your one-of-a-kind body. Here, one woman shares her Contrave for weight loss success story of how she shed ...

WASHINGTON (AP) — U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation’s 78 million obese ...

Program ensures continued access to treatment for patients enrolled in the Federal Employee & Retirees Health Plan (FEP) BRENTWOOD, Tenn., Oct. 23, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC, a ...

CONTRAVE, approved in the U.S. and marketed in Europe as MYSIMBA, has been studied extensively in both randomized clinical trials and observational settings. The latest analysis builds upon prior ...

Contrave, the weight loss pill that combats food cravings, has launched its first-ever TV commercial-- with audio that features new lyrics to Lesley Gore’s 62-year-old feminist anthem “You Don’t Own ...

When compared to placebo, patients treated with CONTRAVE showed significant improvements in positive mood, reduced cravings for savory foods, and overall greater control of cravings. The study further ...